Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia

@article{Schmidt2008PreclinicalCO,
  title={Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia},
  author={C. Schmidt and D. Chapin and J. Cianfrogna and M. Corman and M. Haj{\'o}s and J. Harms and W. Hoffman and L. Lebel and S. McCarthy and F. Nelson and C. Proulx-Lafrance and M. Majchrzak and A. Ramirez and K. Schmidt and P. Seymour and J. Siuciak and F. Tingley and R. Williams and P. Verhoest and F. Menniti},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  year={2008},
  volume={325},
  pages={681 - 690}
}
We have recently proposed the hypothesis that inhibition of the cyclic nucleotide phosphodiesterase (PDE) 10A may represent a new pharmacological approach to the treatment of schizophrenia (Curr Opin Invest Drug 8:54–59, 2007). PDE10A is highly expressed in the medium spiny neurons of the mammalian striatum (Brain Res 985:113–126, 2003; J Histochem Cytochem 54:1205–1213, 2006; Neuroscience 139:597–607, 2006), where the enzyme is hypothesized to regulate both cAMP and cGMP signaling cascades to… Expand
The Role of Phosphodiesterases in Schizophrenia
Phosphodiesterase 10 inhibitors in clinical development for CNS disorders
Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present)
Pharmacological evaluation of a novel phosphodiesterase 10A inhibitor in models of antipsychotic activity and cognition
A Novel Phosphodiesterase 1 Inhibitor DSR-141562 Exhibits Efficacies in Animal Models for Positive, Negative, and Cognitive Symptoms Associated with Schizophrenia
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 60 REFERENCES
Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia.
Inhibition of the striatum-enriched phosphodiesterase PDE10A: A novel approach to the treatment of psychosis
Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase
Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: Evidence for altered striatal function
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial
Immunohistochemical Localization of Phosphodiesterase 10A in Multiple Mammalian Species
Immunohistochemical localization of PDE10A in the rat brain
The Neuropsychopharmacology of Phencyclidine: From NMDA Receptor Hypofunction to the Dopamine Hypothesis of Schizophrenia
Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment.
...
1
2
3
4
5
...